Increasing Prevalence Of Diabetes Fuels Growth In The Gastroparesis Drugs Market Is Supporting Development Across The Gastroparesis Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Gastroparesis Drugs Market Over The Forecast Period?

The gastroparesis drugs market has shown robust expansion in recent years. It is anticipated to increase from $5.7 billion in 2025 to $6.02 billion in 2026, registering a compound annual growth rate (CAGR) of 5.7%. The historical growth in this market can be linked to factors such as the heightened diagnosis of diabetic gastroparesis, the enduring usage of prokinetic and antiemetic drugs, the rising incidence of diabetes-related gastrointestinal disorders, the accessibility of both over-the-counter and prescription symptom relief medications, and the expansion of gastroenterology care services.

The gastroparesis drugs market is projected to experience substantial expansion in the upcoming years, with its size anticipated to reach $7.37 billion in 2030, growing at a compound annual growth rate (CAGR) of 5.2%. This expected growth throughout the forecast period is driven by factors such as the increasing global incidence of diabetes, a rising awareness of gastroparesis as a chronic condition, a heightened demand for effective long-term symptom management, improved access to specialty gastrointestinal care, and an ongoing need for better therapies to enhance motility. Key trends during this period are set to include a greater reliance on prokinetic agents for symptom control, an increased adoption of combination drug therapy for gastroparesis, a growing demand for prescription-based gastroparesis treatments, the broadening of symptom-focused treatment approaches, and a more extensive use of oral drug formulations for long-term management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

What Major Growth Factors Are Impacting The Gastroparesis Drugs Market?

The increasing occurrence of diabetes is anticipated to drive the expansion of the gastroparesis drugs market moving forward. Diabetes is a chronic metabolic condition defined by elevated blood sugar levels, resulting from insufficient insulin generation or ineffective insulin utilization. The prevalence of diabetes is escalating due to factors such as sedentary lifestyles, unhealthy dietary practices, genetic predispositions, urbanization, an aging demographic, and rising obesity rates. The gastroparesis drugs market supports diabetes care by supplying medications that alleviate symptoms like nausea, vomiting, and delayed gastric emptying, which are common gastrointestinal complications associated with diabetic gastroparesis. For instance, in March 2024, information from the Office for Health Improvement & Disparities, a UK-based government department, revealed that between March 2022 and March 2023, the number of individuals with type 1 diabetes receiving all eight recommended care processes saw a 22% increase, while type 2 diabetes patients experienced a 21% rise, and the percentage reaching target HbA1c levels climbed to 37.9%, which was the highest value ever reported by the National Diabetes Audit. Thus, the growing prevalence of diabetes is stimulating the growth of the gastroparesis drugs market.

What Are The Major Segment Categories Within The Gastroparesis Drugs Market?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

What Trends Are Shaping The Gastroparesis Drugs Market Structure?

Leading firms within the gastroparesis drugs market are concentrating on creating cutting-edge remedies, including new prokinetic treatments, to enhance stomach movement and alleviate associated symptoms. These novel prokinetic therapies represent fresh pharmaceutical approaches intended to stimulate and improve the natural propulsion of the stomach and bowels, thereby facilitating more efficient food transit. As an illustration, in December 2023, Vanda Pharmaceuticals Inc., a biopharmaceutical firm based in the US, secured approval from the U.S. Food and Drug Administration (FDA) to proceed with its New Drug Application (NDA) for tradipitant, aimed at managing gastroparesis symptoms. This acceptance pertains to tradipitant, an experimental oral neurokinin-1 receptor antagonist, designated for addressing gastroparesis, a severe digestive condition characterized by significant unaddressed medical requirements. Such approval signifies a crucial regulatory achievement for Vanda as the company persists in seeking market authorization for tradipitant for individuals suffering from gastroparesis.

Who Are The Prominent Players Across The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Access The Complete Gastroparesis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Has The Strongest Presence In The Gastroparesis Drugs Market?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gastroparesis Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795